Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019320 | 0.81 | LPL (0.41) | LPLLIPGIRAK4FFAR1CA1 | |
| SCHEMBL2023563 | 0.80 | LPL (0.49) | LPLLIPGIRAK4FFAR1CA1 | |
| SCHEMBL20006903 | 0.76 | LPL (0.53) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL12099753 | 0.76 | LPL (0.45) | LPLLIPGIRAK4FFAR1CA1 | |
| SCHEMBL15299275 | 0.75 | HTT (0.49) | LPLLIPGIRAK4CA1CA2 | |
| SCHEMBL15299280 | 0.73 | LPL (0.45) | LPLLIPGIRAK4FFAR1CA1 | |
| SCHEMBL228212 | 0.73 | LPL (0.71) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL15299297 | 0.72 | LPL (0.44) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL1839301 | 0.72 | LPL (0.41) | LPLLIPGIRAK4FFAR1CA1 | |
| SCHEMBL15986832 | 0.71 | LPL (0.50) | LPLLIPGCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2683689-B1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2017-04-12 | — | — | EP | disclosed |
| US-8779148-B2 | Fluoro-pyridinone derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140057919-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2683689-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8624034-B2 | Fluoro-pyridinone derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20120232083-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC | 2012-09-13 | — | — | US | disclosed |
| WO-2012120397-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232083-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PRDX1, PRXL2A, PRDX4 | LPL 671/4885LIPG 1488/4885IRAK4 744/4885 |
| US-20140057919-A1 | FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PRDX1, PRXL2A, PRDX4 | LPL 671/4885LIPG 1488/4885IRAK4 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.